It is important to mention that inhibition of IL-10 production by T cells or malignant cells, using low-dose cyclophosphamide [62], anti-IL-10/IL-10R-blocking antibodies [63, 64], or anti-IL-10 antisense oligonucleotides [65], improves cancer-specific immune responses in some preclinical tumor models, which leads the authors to advocate the use of IL-10-neutralizing agents as immunological adjuvants in the design of anticancer vaccines [53]. This evidence concerns the gene IL10 and neoplasm.